Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
about
Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.Chemotherapy of secondary leukemias.Therapy related leukemias: susceptibility, prevention and treatment.Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy.The role of intensive chemotherapy in myelodysplastic syndromes.Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).De-novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) and myelodysplastic remission marrow (AML/MRM).Myelodysplastic syndromes in childhood--classification, epidemiology, and treatment.Application of low-dose etoposide therapy for myelodysplastic syndromes.Prognostic implications in myelodysplastic syndromes: A review of 62 cases.Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK aQuinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood
P2860
Q33492683-6B27D8B7-493B-4CD4-867D-5499D849EA72Q34066666-A13A08E4-2845-46C7-AA34-C233EFD29D9BQ34265193-24D28DA3-1307-40F8-9198-DC76CF0EB7B7Q34680950-468FC3E7-49D3-43CD-94CE-FD5D8BF60B43Q35664739-616A6060-AD7F-43F9-81AA-521942DD67A4Q36158816-6CB1D2BC-B73E-492D-97C8-75F4ACB430BAQ40507927-E5210904-45EF-46C7-9021-FE0558F75CD8Q40668687-9467401A-E298-41CC-843B-32E66E0EF9D7Q40742402-3E17FC3C-6032-43DC-9277-4F0512CA9BF2Q41489340-761EDB4C-C5AB-472F-9439-5868D4020D79Q42280826-050AD860-C7C7-45C4-97BA-5EFE87A3E414Q43666936-358D7887-F518-4BC4-9DC5-BD4CFDD59600Q43763239-C111E182-470C-4212-BE26-92128C12C46FQ44443448-4F6D4A8C-1A50-4298-A9A3-C4C7E73D274FQ54125443-442D9CB0-DEDB-4B6C-B681-B459ABD84ACFQ57515100-1833E189-509B-4681-8DB7-C52B5FE08173
P2860
Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Intensive antileukemic treatme ...... ry acute myelogenous leukemia.
@ast
Intensive antileukemic treatme ...... ry acute myelogenous leukemia.
@en
type
label
Intensive antileukemic treatme ...... ry acute myelogenous leukemia.
@ast
Intensive antileukemic treatme ...... ry acute myelogenous leukemia.
@en
prefLabel
Intensive antileukemic treatme ...... ry acute myelogenous leukemia.
@ast
Intensive antileukemic treatme ...... ry acute myelogenous leukemia.
@en
P2093
P1433
P1476
Intensive antileukemic treatme ...... ry acute myelogenous leukemia.
@en
P2093
P2860
P304
P356
10.1002/1097-0142(19900901)66:5<831::AID-CNCR2820660503>3.0.CO;2-E
P407
P577
1990-09-01T00:00:00Z